AI assistant
Sending…
Denali Therapeutics Inc. — Director's Dealing 2021
Jan 13, 2021
31637_dirs_2021-01-12_a7de4d1c-0fa7-4cc6-b3cc-6a9cbbefc55a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-01-08
Reporting Person: Thornberry Nancy (Director)
More from Denali Therapeutics Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 3
Regulatory Filings
2026
May 21
Earnings Release
2026
May 7
Annual Report
2026
Apr 21
Regulatory Filings
2026
Apr 3
Capital/Financing Update
2026
Mar 31
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 25
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26